Is an HIV vaccine possible?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.PLoS pathogens · 2020
   Trial
2. HIV-1 prophylactic vaccines: state of the art.Journal of virus eradication · 2016
   Review
3. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.Journal of virology · 2006
   Article
4. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.Proceedings of the National Academy of Sciences of the United States of America · 2001
   Article
5. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.Infection and immunity · 1999
   Article
6. Immunotherapy of cancer in 2012.CA: a cancer journal for clinicians
   Review
7. Construction of an artificial immunogen, a candidate DNA vaccine encoding multiple CTL epitopes of HIV-1.Doklady. Biochemistry and biophysics
   Article

Corrections and comments

• Comment on
  Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.1999
• Comment on
  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.1999

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as